Quest Diagnosticsvs.Natera
DGX vs NTRA · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Natera is about 2.3× larger than Quest Diagnostics by market cap; year to date, Natera leads (+70.6% vs +33.0%).
Side by side
| DGX | NTRA | |
|---|---|---|
| Market cap | $25.4B | $57.6B |
| Price | $230.97 | $400.71 |
| Today | +0.1% | +2.5% |
| Return YTD | +33.0% | +70.6% |
| Return 1Y | +27.6% | +127.1% |
| Since June 26, 2026 | +10.0% | +53.0% |
| P/E | 23.9 | — |
| P/S | 2.2 | 21.3 |
| P/B | 3.4 | 31.6 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Quest DiagnosticsDGX
A nationwide lab network that does routine testing at volume, with more advanced diagnostics and health data work on top.
Full DGX profile →NateraNTRA
Genetic testing put to three uses: Panorama screens pregnancies, Signatera works in oncology, and a third line covers transplant medicine.
Full NTRA profile →More DGX & NTRA comparisons
Other head-to-heads in the Diagnostics segment.
See where DGX and NTRA sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →